RecruitingNot ApplicableNCT06859177

Feasibility of Remote eCTG Monitoring Home@Hospital in Complicated Pregnancies

Remote Electrophysiological Cardiotocography (eCTG), Evaluation of Feasibility in (a Selected Group of) Complicated Pregnancies From 32 Until 37 Weeks Gestational Age in a Home@Hospital Setting: a Prospective Cohort Study


Sponsor

Maxima Medical Center

Enrollment

60 participants

Start Date

Mar 25, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The objective of this single center, interventional cohort study is to evaluate the feasibility of remote electrophysiological cardiotocography (eCTG) monitoring in complicated pregnancies in a home@hospital setting. The primary objective is to assess: • The success rate of the self-administered eCTG measurement The secondary objective is to asses: * Maternal and perinatal outcomes * Patients wellbeing and satisfaction. * Healthcare professionals' (HCPs') satisfaction * Analysis of antenatal costs Participants will: * Self-administer remote eCTG monitoring once daily during admission (or at least twice weekly at the outpatient clinic) * Self-measure their blood pressure, heartrate and temperature * Enter the measurements, symptoms and worries into an application on their telephone. * Answer questionnaires at 3 moments during the study, assessing their wellbeing and satisfaction of the received care and self-administered remote monitoring device.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria8

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • Minimum age of 18 years old
  • Pregnant patients with a gestational age between 32+0 and 36+6 weeks and days
  • Singleton pregnancy
  • Any indication for fetal monitoring at least twice per week (e.g.):
  • Pre-eclampsia (PE)
  • Fetal growth restriction (FGR)
  • Preterm pre-labor rupture of membranes (PPROM)

Exclusion Criteria18

  • Oral and written informed consent is obtained.
  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • An indication for intravenous medication
  • Blood pressure \>160/110 A millimeter of mercury (mmHg)
  • Absent-/or reversed flow umbilical artery Doppler
  • Hemolysis Elevated Liver enzymes and Low Platelets (HELLP) (Table 1)
  • Obstetric intervention expected \<48 hours, e.g. due to:
  • Non reassuring cardiotocography (CTG)
  • Active vaginal blood loss
  • Signs of abruption placentae
  • Meconium stained amniotic fluid
  • Signs of chorioamnionitis
  • Patients admitted with a clinical diagnosis of sepsis with hypotension (i.e. septic shock).
  • Insufficient knowledge of Dutch or English language
  • Insufficient comprehension of instruction Nemo Remote® or patient information
  • Fetal and/or maternal cardiac arrhythmias
  • Contraindications to abdominal patch placement (dermatologic diseases of the abdomen precluding preparation of the abdomen with abrasive paper)
  • Patients connected to an external or implanted electrical stimulator, such as Transcutaneous Electro Neuro Stimulation (TENS) and pacemaker (because of disturbance of the electrophysiological signal).

Interventions

DEVICERemote eCTG

Device: Remote eCTG monitoring A remote self-administered electrophysiological cardiotocography (eCTG) monitoring (using Nemo Remote®), daily in a Home@Hospital setting, or at least twice weekly at the outpatient clinic, between 32 and 37 weeks of pregnancy.


Locations(1)

Maxima Medical Center

Veldhoven, North Brabant, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06859177


Related Trials